Clinical trials: High-grade Serous Ovarian Cancer
High-grade Serous Ovarian Cancer (HGSOC)
Prediction of Platinum Resistance and Prognosis of High-grade Serous Ovarian Cancer
High-grade serous ovarian carcinoma (HGSOC) is the most common subtype of ovarian carcinoma. Platinum-based drugs are the first-line chemotherapeutic agents for HGSOC, but platinum resistance and prognosis are difficult to…
- Trial name
- PPRPHGSOC (NCT06787170)
- Testing
- MRI habitat imaging
- Where
- China
- Volunteers
- 1,129 people
- Sponsor
- The First People's Hospital of Yunnan
Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
This phase I/IB trial tests the safety, side effects, and best dose of ipatasertib in combination with paclitaxel and carboplatin in treating patients with stage III or IV epithelial ovarian cancer.
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
- Trial name
- NCT05276973
- Testing
- Biopsy Procedure, Carboplatin, Ipatasertib
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Gynecologic Cancer
Study Looking at Biomarkers in Ovarian Cancer
This is a sample study that will collect biological samples (blood, tumor tissue, ascites, and/or other fluids) from gynecological cancer patients for biomarker research.
- Trial name
- NCT03419689
- Testing
- Tumour tissue collection, Blood sample collection, Ascites Collection
- Where
- 7 sites in Canada
- Volunteers
- 510 people
- Sponsor
- University Health Network, Toronto
Ovarian Cancer, Breast Cancer
Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer
This research study is a Phase I clinical trial. Phase I clinical trials test the safety of an investigational combination of drugs.
- Trial name
- NCT01623349
- Testing
- BKM120 and Olaparib, BYL719 and Olaparib
- Where
- 5 sites in United States
- Volunteers
- 118 people
- Sponsor
- Dana-Farber Cancer Institute
Platinum-resistant Ovarian Cancer
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
This is a phase Ib/II, open label clinical study to evaluate the safety, tolerability and antitumor activities of IN10018 in combination with standard chemotherapy in subjects with high-grade serous ovarian cancer (including…
- Trial name
- NCT05551507
- Testing
- IN10018 in combination with PLD
- Where
- 7 sites in China
- Volunteers
- 150 people
- Sponsor
- InxMed (Shanghai) Co., Ltd.
Ovarian Cancer, Fallopian Tube Cancer
Vinorelbine in Relapsed Platinum Resistant or Refractory C5 High Grade Serous, Endometrioid, or Undifferentiated Primary Peritoneum, Fallopian Tube or Ovarian Cancer
This is a phase II study in patients with recurrent platinum resistant or refractory C5 high-grade serous, endometrioid or undifferentiated ovarian, primary peritoneal or fallopian tube cancer.
- Trial name
- NCT03188159
- Testing
- Vinorelbine
- Where
- 2 sites in Australia, Singapore
- Volunteers
- 36 people
- Sponsor
- National University Hospital, Singapore
Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma
Adavosertib Before Surgery in Treating Patients With Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This pilot early phase I trial studies how adavosertib affects the tumor deoxyribonucleic acid (DNA) of patients undergoing surgery for high grade (fast growing or aggressive) ovarian, fallopian tube, or primary peritoneal cancer…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Ovarian Carcinoma, Advanced Primary Peritoneal Carcinoma, Carcinomatosis
- Trial name
- NCT02659241
- Testing
- Adavosertib, Laboratory Biomarker Analysis
- Where
- 8 sites in United States
- Volunteers
- 38 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm
Olaparib and Onalespib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer
This phase I trial studies the side effects and best dose of olaparib and onalespib when given together in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by…
- Conditions
- Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT02898207
- Testing
- Olaparib, Onalespib
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- National Cancer Institute (NCI)
To Investigate the Prevalence of BRCA 1/2 Mutation Among Ovarian Cancer
BRCA 1/2 Mutation in Korean Patients With Epithelial Ovarian Cancer
PURPOSE: To investigate the prevalence and clinical correlation of the germline BRCA 1/2 mutation in Korean patients with high grade(HG) serous and/or endometrioid epithelial ovarian cancer (EOC).
- Trial name
- NCT02963688
- Testing
- Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform
- Volunteers
- 298 people
- Sponsor
- Samsung Medical Center
Triple Negative Breast Cancer, Non-small Cell Lung Cancer
A Biomarker Screening Protocol for Participants With Solid Tumors
Biomarker Screening Protocol for Preliminary Eligibility Determination for Adoptive T-cell Therapy Trials:This is a decentralized, multi-site, US-based biomarker screening study to identify participants who have specific disease…
- Conditions
- Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
- Trial name
- START (NCT05891197)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Lyell Immunopharma, Inc.
Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma
Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma
This phase II trial studies how well autologous tumor infiltrating lymphocytes MDA-TIL works in treating patients with ovarian cancer, colorectal cancer, or pancreatic ductal adenocarcinoma that has come back (recurrent) or does…
- Conditions
- Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT03610490
- Testing
- Autologous Tumor Infiltrating Lymphocytes MDA-TIL, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Ovarian Cancer, Ovarian Neoplasms
Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)
DICE is a randomised study recruiting 126 women over 3 years from hospitals in the UK and Germany. Eligible patients will have tissue based diagnosis of advanced/recurrent ovarian cancer (clear cell, endometrioid or high grade…
- Conditions
- Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinosarcoma, Ovarian Serous Adenocarcinoma
- Trial name
- DICE (NCT03648489)
- Testing
- Paclitaxel, TAK228
- Where
- 15 sites in Germany, United Kingdom
- Volunteers
- 134 people
- Sponsor
- Imperial College London
Ovarian High Grade Serous Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
This phase II trial test tests how well repurposing atovaquone works in treating patients with platinum-resistant ovarian cancer. Atovaquone is used for the treatment or prevention of certain infections.
- Trial name
- NCT05998135
- Testing
- Atovaquone, Biopsy, Computed Tomography
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Emory University
Epithelial Ovarian Cancer, Fallopian Tube Cancer
GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer
Epithelial ovarian cancer (EOC) is the most lethal gynaecological malignancy causing 41900 deaths annually in Europe. The predominance of aggressive Type II tumours, which are characterised by a high frequency of p53 mutations…
- Conditions
- Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT02012192
- Testing
- Ganetespib, Paclitaxel
- Where
- 10 sites in Austria, Belgium and 2 more
- Volunteers
- 133 people
- Sponsor
- Medical University Innsbruck
Advanced Ovarian Cancer (Stage III or IV) After Neoadjuvant Chemotherapy, High-grade Serous Ovarian Carcinoma
Prognostic Value of KELIM Score and Inflammatory Markers in Ovarian Cancer
This is a retrospective observational study to evaluate the integrative prognostic value of inflammatory markers, specifically the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR), alongside the CA-125…
- Trial name
- NCT07678008
- Where
- Egypt
- Volunteers
- 80 people
- Sponsor
- Aya Ahmed Nasser
Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer
Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with…
- Conditions
- Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- NCT05281471
- Testing
- olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin (preferred) or cisplatin, Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin
- Where
- 33 sites in United States
- Volunteers
- 186 people
- Sponsor
- Genelux Corporation
Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma
Talazoparib in Determining Genetic Effects on Disease Response in Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This pilot early phase I trial studies talazoparib to determine if certain characteristics of the deoxyribonucleic acid (DNA) affect how the disease responds to therapy in patients with ovarian, fallopian tube, or primary…
- Conditions
- Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Ovarian Mass, Primary Peritoneal Serous Adenocarcinoma
- Trial name
- POSITION (NCT02316834)
- Testing
- Laboratory Biomarker Analysis, BMN 673
- Where
- 6 sites in United States
- Volunteers
- 4 people
- Sponsor
- M.D. Anderson Cancer Center
Neoplasms, Ovarian
A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
The purpose of the study is to assess the safety, tolerability, and efficacy of farletuzumab ecteribulin (MORAb-202) and compare it to Investigator's choice (IC) chemotherapy in female participants with platinum-resistant HGS…
- Trial name
- NCT05613088
- Testing
- MORAb-202, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 50 sites in United States, Australia and 7 more
- Volunteers
- 106 people
- Sponsor
- Bristol-Myers Squibb
Ovarian Neoplasm Epithelial, High Grade Serous Carcinoma
Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients
This study is a phase II clinical trial to evaluate the safety and efficacy of Bortezomib plus Pegylated liposomal doxorubicin combination therapy in a histologic type of high-grade serous carcinoma without BRCA mutation among…
- Trial name
- NCT03509246
- Testing
- Pegylated liposomal doxorubicin plus Bortezomib
- Where
- South Korea
- Volunteers
- 44 people
- Sponsor
- Seoul National University Hospital
Ovarian Cancer
ASTRA Study: Circulating Tumor Cells in Blood of Patients With High-Grade Serous Ovarian Cancer
High-grade serous ovarian cancer is typically diagnosed at an advanced stage and remains associated with poor long-term survival. Reliable biomarkers for predicting disease course and treatment response are still limited.
- Trial name
- NCT07439328
- Testing
- Peripheral Blood Collection for CTC Isolation and Analysis
- Where
- Slovenia
- Volunteers
- 30 people
- Sponsor
- Institute of Oncology Ljubljana